You're here because you saw something real.

200 million Americans live with chronic inflammation. We're building the consumer health agent — and the brands — to actually help them. Here's the opportunity underneath that mission.

200M
US adults with chronic inflammation
3
Brands live · 4 launching 2026
78%
Symptom reduction, 90-day pilot
85%
Customer retention rate

The shift

This isn't a someday future — it's already here. Clinically backed consumer brands for the inflammation generation.

Where most people are: managing it, not solving it.

Now within reach: less effort, better days.

The engine

We match biological signals with novel ingredients to scale consumer brands in weeks, not quarters — not months or years like legacy CPG.

A specific symptom → a precision strain + prebiotic formula → a consumer brand, shipped and scaling.

"We are an AI-native company. R3VY informs the engine. The engine executes research, formulation, creative, and channel ops as one system."

Haig Newton · CEO, R3VY

The window

+2,300% custom probiotic searches YoY. +340% gut-brain axis publications. $3B+ in recent CPG health acquisitions. Four tailwinds converging now.

The moat

Six proprietary assets, four exclusive partnerships. The moat isn't just the research — it's the distribution and execution.

The ask

Raising our seed: $1.0M round, $400K committed, $5.0M valuation cap, 20% discount. SAFE note.

Want the full investor summary?

We'll send the complete deck — market, traction, financials, and the ask.

Request investor info →